exosomes derived from human umbilical cord blood mesenchymal stem cells

Exosomes derived from human umbilical cord blood mesenchymal stem cells (UC-MSC-Exos) are nanosized extracellular vesicles secreted by mesenchymal stem cells isolated from human umbilical cord blood. These exosomes contain a variety of bioactive molecules including proteins, lipids, and nucleic acids (such as miRNAs), and mediate intercellular communication. They retain many therapeutic properties of their parent MSCs—most notably immunomodulation, promotion of tissue regeneration, angiogenesis stimulation, anti-inflammatory effects, and tumor suppression. Mechanistically, these exosomes can modulate signaling pathways such as Wnt/β-catenin and MAPK; they also influence cell differentiation and immune responses through the delivery of regulatory RNAs and proteins to target cells. UC-MSC-derived exosome therapy is being investigated in clinical trials for a range of indications including wound healing (notably skin rejuvenation), neurodegenerative diseases like motor neuron disease/ALS and Alzheimer's disease, osteoarthritis/joint disorders, cardiovascular repair after myocardial infarction or stroke injury, among others[1][3][4][6][8]. The product is considered a cell-free biologic therapy with potential advantages over direct MSC transplantation due to reduced risk of infusional toxicity or cellular rejection.

Other names

exosomes from human umbilical cord blood MSCsUC-MSC-derived exosomeshUCB-MSC-Exos